Macrophage migration inhibitory factor contributes to the development of acute dextran sulphate sodium-induced colitis in Toll-like receptor 4 knockout mice

Clinical and Experimental Immunology

Volumn 141, Issue 3, 2005, Pages 412-421

  Ohkawara, Tatsuya ^a,b   Takeda, H ^a   Nishihira, J ^b   Miyashita, K ^a   Nihiwaki, M ^b   Ishiguro, Y ^c   Takeda, K ^d   Akira, S ^e   Iwanaga, T ^a   Sugiyama, T ^f   Asaka, M ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b GeneticLab Co Ltd   (Japan)

^c HIROSAKI UNIVERSITY   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

^e OSAKA UNIVERSITY   (Japan)

^f UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Dextran sulphate sodium induced colitis; Inflammatory bowel disease; Inhibitory factor; Macrophage migration; Toll like receptor 4

Indexed keywords

ANTIBODY; COLLAGENASE 3; DEXTRAN SULFATE; DRINKING WATER; LIPOPOLYSACCHARIDE; MACROPHAGE MIGRATION INHIBITION FACTOR; MACROPHAGE MIGRATION INHIBITION FACTOR ANTIBODY; MYELOPEROXIDASE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL FEATURE; COLITIS; COLON; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; ENZYME ACTIVITY; HISTOPATHOLOGY; INNATE IMMUNITY; KNOCKOUT MOUSE; MACROPHAGE MIGRATION; MALE; MOUSE; NONHUMAN; NULL ALLELE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; UPREGULATION; WILD TYPE;

ACUTE DISEASE; ANIMALS; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; COLITIS, ULCERATIVE; COLON; DEXTRAN SULFATE; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEROXIDASE; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 23044457720     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2005.02877.x     Document Type: Article

References (52)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347:417-29.
2. Sartor RB. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol 1997; 92:5S-11S.
3. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 2000; 51:289-98.
4. de Jong YP, Abadia-Molina AC, Satoskar AR et al. Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol 2001; 2:1061-6.
5. Ohkawara T, Nishihira J, Takeda H et al. Amelioration of dextran sulfate sodium-induced colitis by anti-macrophage migration inhibitory factor antibody in mice. Gastroenterology 2002; 123:256-70.
6. van Dullemen HM, van Deventer SJ, Hommes DW et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109:129-35.
7. Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337:1029-35.
8. Ito H, Takazoe M, Fukuda Y et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004; 126:989-96.
9. Hugot JP, Chamaillard M, Zouali H et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411:599-603.
10. Ogura Y, Bonen DK, Inohara N et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6.
11. Medzhitov R, Preston-Hurburt P, Janeway Jr. CA et al. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 2001; 388:394-7.
12. Medzhitov R, Janeway Jr. CA Innate immunity: the virtues of a nonclonal system of recognitioN. Cell 1997; 91:295-8.
13. O'Neill LA, Greene C. Signal transduction pathways activated by the IL-1 receptor family, ancient signaling machinery in mammals, insects, and plants. J Leuk Biol 1998; 63:650-7.
14. Rock FL, Hardiman G, Timans JC et al. A family of human receptors structurally related to Drosphila Toll. Proc Natl Acad Sci USA 1998; 95:588-93.
15. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21:335-76.
16. Hoshino K, Takeuchi O, Kawai T et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 1990; 162:3749-52.
17. Helga-Paula T, Jurgen G, Laurian T et al. Polymorphisms of the lipopolysaccharide-signaling complex in inflammatory bowel disease: association of a mutation in the Toll-like receptor 4 gene with ulcerative colitis. Clin Immunol 2004; 112:85-91.
18. Franchimont D, Vermeire S, Housni HE et al. Deficient host-bacteria interactions in inflammatory bowel disease? The Toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crhon's disease and ulcerative colitis. Gut 2004; 53:987-92.
19. Hornef MW, Frisan T, Vandewalle A et al. Toll-like receptor 4 resides in the Golgi apparatus and colocalizes with internalized lipopolysaccharide in intestinal epithelial cells. J Exp Med 2002; 195:559-70.
20. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of Toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000; 68:7010-7.
21. Ortega-Cava CF, Ishihara S, Rumi MAK. Strategic compartmentalization of Toll-like receptor 4 in the mouse gut. J Immunol 2003; 170:3977-85.
22. Bloom BR, Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 1966; 153:80-2.
23. David JR. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA 1966; 56:72-7.
24. Bucala R. MIF re-discovered: pituitary hormone and glucocorticoid-induced regulator of cytokine production. FASEB J 1996; 7:19-24.
25. Nishihira J. Macrophage migration inhibitory factor (MIF): its essential role in the immune system and cell growth. J Interferon Cytokine Res 2000; 20:751-62.
26. Calandra T, Bernhagen J, Mitchell RA et al. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994; 179:1895-902.
27. Bacher M, Metz CN, Calandra T et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 1996; 93:7849-54.
28. Calandra T, Echtenacher B, Roy DL et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000; 6:164-70.
29. Kobayashi S, Nishihira J, Watanabe S et al. Prevention of lethal acute hepatic failure by anti-macrophage migration inhibitory factor in mice treated with bacilli Calmette-Guérin and lipopolysaccharide. Hepatology 1999; 29:1752-9.
30. Hirokawa J, Sakaue S, Tagami S et al. Identification of macrophage migration inhibitory factor in adipose tissue and its induction by tumor necrosis factor-α. Biochem Biophys Res Commun 1997; 235:94-8.
31. Shimizu T, Ohkawara A, Nishihira J et al. Identification of macrophage migration inhibitory factor (MIF) in human skin and its immmunohistochemical localization. FEBS Lett 1996; 381:199-202.
32. Nishihira J, Kuriyama T, Sakai M et al. The structure and physicochemical properties of rat liver macrophage migration inhibitory factor. Biochim Biophys Acta 1995; 1247:159-62.
33. Cooper HS, Murthy SN, Shah RS et al. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993; 69:238-49.
34. Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 1984; 87:1344-50.
35. Onodera S, Kaneda K, Mizue Y et al. Macrophage migration inhibitory factor up-regulates expression of matrix metalloproteinases in synovial fibroblasts of rheumatoid arthritis. J Biol Chem 2000; 275:444-50.
36. Okayasu I, Hatakeyama S, Yamada M et al. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990; 98:694-702.
37. Dieleman LA, Palmen MJ, Akol H et al. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 1998; 114:385-91.
38. Sivakumar PV, Westrich GM, Kanaly S et al. Interleukin 18 is a primary mediator of the inflammation associated with dextran sulphate sodium induced colitis: blocking interleukin 18 attenuates intestinal damage. Gut 2002; 50:812-20.
39. Ohkawara T, Miyashita K, Nishihira J et al. Transgenic overexpression of macrophage migration inhibitory factor renders mice markedly more susceptible to experimental colitis. Clin Exp Immunol 2005; 140:241-8.
40. Dieleman LA, Ridwan BU, Tennyson GS et al. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 1994; 107:1643-52.
41. Stevceva L, Pavli P, Buffinton G et al. Dextran sodium sulphate-induced colitis activity varies with mouse strain but develops in lipopolysaccharide- unresponse mice. J Gastroenterol Hepatol 1999; 14:54-60.
42. Araki A, Kanai T, Ishikura T et al. MyD88-deficient mice develop severe intestinal inflammation in dextran sodium sulfate colitis. J Gastroenterol 2005; 40:16-23.
43. Kojouharoff G, Hans W, Obermeier F et al. Neutralization of tumor necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin Exp Immunol 1997; 107:353-8.
44. Bozza M, Satoskar ARG, Lin G et al. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med 1999; 189:341-6.
45. Roger T, David J, Glauser MP et al. MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature 2001; 414:920-4.
46. Kojouharoff G, Hans W, Obermeier F et al. Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin Exp Immunol 1997; 107:353-8.
47. Naito Y, Takagi T, Handa O et al. Enhanced intestinal inflammation induced by dextran sulfate sodium in tumor necrosis factor-alpha deficient mice. J Gastroen Hepatol 2003; 18:560-9.
48. Murakami H, Akbar SM, Matsui H et al. Macrophage migration inhibitory factor in the sera and at the colonic mucosa in patients with ulcerative colitis: clinical implications and pathogenic significance. Eur J Clin Invest 2001; 31:337-43.
49. Huang XR, Chun Hui CW, Chen YX et al. Macrophage migration inhibitory factor is an important mediator in the pathogenesis of gastric inflammation in rats. Gastroenterology 2001; 121:619-30.
50. Maaser C, Eckmann L, Paesold G et al. Ubiquitous production of macrophage migration inhibitory factor by human gastric and intestinal epithelium. Gastroenterology 2002; 122:667-80.
51. Matsuda A, Tagawa Y, Matsuda H et al. Identification and immunohistochemical localization of macrophage migration inhibitory factor in human cornea. FEBS Lett 1996; 385:225-8.
52. Makita H, Nishimura M, Miyamoto K et al. Effect of antimacrophage migration inhibitory factor antibody on lipopolysaccharade- induced pulmonary neutrophil accumulation. Am J Respir Crit Care Med 1998; 158:573-9.